Merrell Dow Pharmaceuticals, Inc. (1993) In its 1993 decision Daubert v. Merrell Dow Pharmaceuticals, Inc. , the US Supreme Court established the Daubert Standard for evaluating the admissibility of scientific knowledge as evidence in US federal courts.
But Daubert challenges do have a place when a more thorough examination of an expert’s qualifications are needed. If granted, a Daubert challenge guarantees that the court will extensively review the admissibility requirements of Federal Rule of Evidence 702.
Broadening the range of cases to which Daubert pertains, the Supreme Court held that the standard applies to witnesses that have non-scientific “technical, or other specialized knowledge” as specified in Rule 702.
In 2019, the court reversed course and adopted Daubert as a procedural rule.  Daubert and Frye are two distinct trial court standards for deciding the reliability of expert testimony for admission.